[ET Net News Agency, 20 September 2021] HUTCHMED (China) Limited (00013) said it has
initiated a Japan registration-enabling bridging study for surufatinib to support the
registration of surufatinib in the treatment of patients with advanced neuroendocrine
tumours (NETs). The first patient was dosed on 15 September 2021.
Surufatinib is the third potential new medicine discovered by HUTCHMED to enter into
clinical development in Japan. (RC)